[Correspondence] Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply We thank Yunfeng Fu and colleagues for their important comments on the IFM2017-03 trial1. We provide below the most accurate information available to address their remarks. The Lancet Oncology February 28, 2026 Original source
[Correspondence] Daratumumab–lenalidomide and the immunosuppressive budget in myeloma Salomon Manier and colleagues show that, in patients aged 65 years or older with newly diagnosed multiple myeloma selected for frailty, a regimen of lenalidomide plus daratumumab with dexamethasone confined to the first two cycles achieves markedly longer progression-free survival than continuous lenalidomide–dexamethasone, with an accompanying overall survival benefit and no clear excess of serious infections.1 For a population in… The Lancet Oncology February 28, 2026 Original source
[Comment] Thank you to The Lancet Oncology's reviewers in 2025 Alfredo Addeo The Lancet Oncology February 28, 2026 Original source
[Comment] Greater transparency for oncology clinical trials reporting Over recent decades, advances in cancer treatment have yielded substantial improvements in patient outcomes, driving up survival, and even rendering some cancers curable. These advances have been achieved not only by remarkable scientific breakthroughs, but also by unprecedented financial investment in research and development, including the conduct of clinical trials of a size and complexity only feasible by the involvement… The Lancet Oncology February 28, 2026 Original source
[Comment] Time to act: a global call for oral cancer prevention and early detection Oral cancer, ranked among the 16th most common cancers globally, represents a major public health burden.1 In some countries in south Asia, oral cancer is the most frequent cancer among men. A recent systematic analysis for the Global Burden of Disease study concluded that insufficient action in the past three decades has led to little change in population oral health,… The Lancet Oncology February 28, 2026 Original source
[Comment] Media coverage and PATHFINDER2: hype, simplification, and free advertising The recent media coverage of interim results from the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test exemplifies a troubling and recurring trend in science communication: the commercially driven, premature framing of non-peer-reviewed data as proof of a transformative breakthrough. Released via an embargoed press statement on Oct 17, 2025, and then presented as a late-breaking abstract at the… The Lancet Oncology February 28, 2026 Original source
[Comment] Sharing patient-reported outcomes with clinical investigators in real time In cancer trials, clinical investigators report and grade adverse events on behalf of their patients via the Common Terminology Criteria for Adverse Events (CTCAE) scale—including for highly subjective events such as fatigue, nausea, or sensory neuropathy. However, this approach has been found to be unreliable. The Lancet Oncology February 28, 2026 Original source
[Comment] Concordant phase 2 evidence and biological plausibility for rare tumours Clear cell gynaecological tumours represent a paradigmatic example of the challenges of rare cancers, in which scarce clinical evidence contrasts with high unmet need, often affecting younger patients and raising concerns about equitable access to innovation. In The Lancet Oncology, Natalie Y L Ngoi and colleagues report the LARA (GCGS-OV4/APGOT-OV3) single-arm, multicentre, phase 2 trial of pembrolizumab plus lenvatinib in… The Lancet Oncology February 28, 2026 Original source
[Comment] Oligometastatic prostate cancer: time to integrate metastasis-directed therapy Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted the management paradigm for metastatic prostate cancer. These pioneering studies showed improved progression-free survival in patients with up to three metastases compared with observation alone (HR 0·60, 95% CI 0·40–0·90 in STOMP; HR 0·30, 0·11–0·81… The Lancet Oncology February 28, 2026 Original source
[Comment] Precision oncology in resected EGFR-mutant NSCLC The therapeutic landscape of early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) has been irreversibly transformed by adjuvant EGFR tyrosine-kinase inhibitors.1 This paradigm shift began with the ADAURA trial, which established postoperative osimertinib as the first adjuvant targeted therapy to deliver durable survival benefit in molecularly defined NSCLC.2,3 Its effects extended beyond recurrence delay, providing clear evidence that early systemic intervention can… The Lancet Oncology February 28, 2026 Original source
[Editorial] Cancer: another casualty of geopolitical unrest? Along with ongoing wars, territorial disputes, and instability in regions such as the Middle East, Europe, Latin America, and parts of Africa, there are continued changes and power shifts in the complex and turbulent geopolitical landscape. Unpredictable decisions with international consequences by the USA, under the leadership of President Donald J Trump, are of particular concern and are causing widespread… The Lancet Oncology February 28, 2026 Original source
Methodological Considerations in “The Nutritional Impact of Childhood Cancer: Insights from a Feasibility Cohort Study” . <br /> Nutrition and Cancer Journal February 28, 2026 Original source
Optimizing Nutritional Support in Advanced Non-Small Cell Lung Cancer: Evidence and Controversies in Oral, Enteral, and Parenteral Approaches . <br /> Nutrition and Cancer Journal February 28, 2026 Original source
Nutritional and Immune State of Gastric Cancer Patients Deteriorate During the Preoperative Period . <br /> Nutrition and Cancer Journal February 28, 2026 Original source
Healthy Eating Index-2020 and Risk of Endometrial Cancer: A Case-Control Study Among Iranian Women . <br /> Nutrition and Cancer Journal February 28, 2026 Original source
Mountain-Cultivated Ginseng in Combination with Acupuncture Inhibits Breast Cancer Growth via PD-1/PD-L1 Degradation Mediated by AMPK-Induced Autophagy . <br /> Nutrition and Cancer Journal February 28, 2026 Original source
The intestinal microbiota as a key modulator of acute graft-versus-host disease <p>Nature Reviews Cancer, Published online: 26 February 2026; <a href="https://www.nature.com/articles/s41568-026-00910-6">doi:10.1038/s41568-026-00910-6</a></p>In this Review, Paredes et al. discuss preclinical and clinical evidence suggesting that the intestinal microbiome influences outcomes of allogeneic haematopoietic cell transplantation and, in particular, graft-versus-host disease and propose that microbiota-focused approaches may improve these clinical outcomes. Nature Reviews Cancer February 27, 2026 Original source
Mutant <i>SRSF2</i>-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing <p>Leukemia, Published online: 26 February 2026; <a href="https://www.nature.com/articles/s41375-026-02892-8">doi:10.1038/s41375-026-02892-8</a></p>Mutant <i>SRSF2</i>-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing Leukemia Journal February 27, 2026 Original source
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. The primary analysis of the EORTC 1333/PEACE-3 study demonstrated that enzalutamide plus radium-223 (Ra223) improved radiological progression-free survival (rPFS) compared to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint was rPFS while overall survival (OS) was a key secondary endpoint. Interim overall survival (OS) results were reported at time of primary analysis. Here, we report… Annals of Oncology February 26, 2026 Original source
Researcher Gains Insight into Rare Genetic Diseases <p>Rare genetic cancers may affect few people, but their complexity makes them powerful windows into how even the most common cancers develop and behave.  Delving into understanding how DNA is damaged and repaired in rare genetic conditions is how physician-scientist Alan D’Andrea, MD, built a foundation of knowledge about Fanconi anemia (FA) – a rare genetic disease of the bone marrow that significantly increases the risk of certain cancers.  In people with ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/02/rare-genetic-disease-research-cancer-insights/" title="Researcher… Dana-Farber Cancer Institute February 26, 2026 Original source